Search results
Showing 136 to 150 of 476 results for %s
ColonFlag for identifying people at risk of colorectal cancer (MIB142)
NICE has developed a medtech innovation briefing (MIB) on ColonFlag for identifying people at risk of colorectal cancer .
RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease (MIB109)
NICE has developed a medtech innovation briefing (MIB) on RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease .
Percutaneous radiofrequency ablation for renal cancer (IPG353)
Evidence-based recommendations on percutaneous radiofrequency ablation of renal cancer. This involves using heat produced through electrodes placed into the tumour to destroy the cancer cells.
View recommendations for IPG353Show all sections
Sections for IPG353
Evidence-based recommendations on trabeculotomy ab interno for open angle glaucoma. This involves using a specifically designed surgical instrument to remove a portion of tissue, with the aim of improving the eye’s drainage pathway.
View recommendations for IPG397Show all sections
Sections for IPG397
Evidence-based recommendations on interspinous distraction procedures for lumbar spinal stenosis causing neurogenic claudication. This involves implanting a device into the space between two back bones to relieve pressure on the nerves and, therefore, pain in the legs.
View recommendations for IPG365Show all sections
Sections for IPG365
NICE has developed a medtech innovation briefing (MIB) on Hemosep for cell salvage .
PleuraFlow Active Clearance Technology for maintaining chest tube patency (MIB125)
NICE has developed a medtech innovation briefing (MIB) on PleuraFlow Active Clearance Technology for maintaining chest tube patency .
This quality standard covers the additional antenatal care for women who are pregnant with twins or triplets that is offered alongside routine antenatal care. It describes high-quality care in priority areas for improvement.
View quality statements for QS46Show all sections
Sections for QS46
- Quality statements
- Quality statement 1: Determining chorionicity and amnionicity
- Quality statement 2: Labelling the fetuses
- Quality statement 3: Composition of the multidisciplinary core team
- Quality statement 4: Care planning
- Quality statement 5: Monitoring for fetal complications
- Quality statement 6: Involving a consultant from a tertiary level fetal medicine centre
- Quality statement 7: Advice and preparation for preterm birth
NICE decision aid: process guide
Remote ECG interpretation consultancy services for cardiovascular disease (MIB152)
NICE has developed a medtech innovation briefing (MIB) on remote ECG interpretation consultancy services for cardiovascular disease .
Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)
Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making
Our forward view highlights the areas we will prioritise in the coming year.
This guideline covers the routine postnatal care that women and their babies should receive in the first 8 weeks after the birth. It includes the organisation and delivery of postnatal care, identifying and managing common and serious health problems in women and their babies, how to help parents form strong relationships with their babies, and baby feeding. The recommendations on emotional attachment and baby feeding also cover the antenatal period.
Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making
Summary of the evidence on insulin degludec for treating type 2 diabetes to inform local NHS planning and decision-making